Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$4.89 -3.2%	$4.40	$3.21 ▼ $12.40	$300.78M	1.4	1.07 million shs	111,632 shs
INZY Inozyme Pharma	$3.98 +0.3%	$2.18	$0.72 ▼ $6.24	$256.96M	2.29	880,950 shs	148,536 shs
TERN Terns Pharmaceuticals	$3.98 -2.9%	$2.94	$1.87 ▼ $11.40	$347.60M	-0.18	1.51 million shs	277,191 shs
XCUR Exicure	$8.96 -4.1%	$10.63	$1.44 ▼ $36.00	$56.61M	3.71	556,438 shs	14,842 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-0.59%	+9.54%	+18.27%	-18.68%	+17.99%
INZY Inozyme Pharma	-0.25%	-0.25%	+236.44%	+297.12%	-15.89%
TERN Terns Pharmaceuticals	+0.99%	+16.81%	+35.76%	+18.84%	-44.07%
XCUR Exicure	-5.55%	-7.98%	-21.25%	-29.35%	+2,568.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLUE Monte Rosa Therapeutics	2.3583 of 5 stars	3.4	1.0	0.0	2.2	3.3	0.6
INZY Inozyme Pharma	3.1555 of 5 stars	4.2	3.0	0.0	2.5	2.5	0.0
TERN Terns Pharmaceuticals	4.26 of 5 stars	3.3	2.0	4.1	3.8	2.5	0.6
XCUR Exicure	1.6397 of 5 stars	0.0	4.0	4.7	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$15.50	216.97% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	195.23% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	292.59% Upside
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, INZY, GLUE, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $10.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$159.49M	1.89	N/A	N/A	$3.58 per share	1.37
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.13 per share	N/A
XCUR Exicure	$500K	113.22	N/A	N/A	$1.75 per share	5.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$135.35M	$0.08	N/A	N/A	N/A	N/A	-62.68%	-38.83%	8/14/2025 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.69	N/A	N/A	N/A	N/A	-88.42%	-57.02%	8/5/2025 (Estimated)
TERN Terns Pharmaceuticals	-$90.21M	-$1.09	N/A	N/A	N/A	N/A	-32.76%	-31.33%	8/4/2025 (Estimated)
XCUR Exicure	-$16.91M	-$4.81	N/A	∞	N/A	N/A	-190.90%	-36.75%	6/16/2025 (Estimated)

Latest XCUR, INZY, GLUE, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
3/20/2025	Q4 2024	GLUE Monte Rosa Therapeutics	-$0.37	$0.23	+$0.60	$0.23	$43.73 million	$14.00 million
3/20/2025	Q4 2024	TERN Terns Pharmaceuticals	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/18/2025	Q4 2024	XCUR Exicure	N/A	-$3.39	N/A	-$3.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	6.03	6.03
INZY Inozyme Pharma	0.51	7.68	7.68
TERN Terns Pharmaceuticals	N/A	32.99	32.99
XCUR Exicure	N/A	0.71	0.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
INZY Inozyme Pharma	88.30%
TERN Terns Pharmaceuticals	98.26%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.90%
INZY Inozyme Pharma	12.18%
TERN Terns Pharmaceuticals	1.50%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.44 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	72.11 million	Not Optionable
XCUR Exicure	50	6.32 million	2.50 million	Not Optionable

XCUR, INZY, GLUE, and TERN Headlines

Recent News About These Companies

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Exicure (NASDAQ:XCUR) Trading Down 4.5% - Here's Why

May 28, 2025 | marketbeat.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.com

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.com

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

Exicure, Inc. Reports Full Year 2024 Financial Results

March 18, 2025 | gurufocus.com

Exicure secures Australian patent for cancer treatment

March 15, 2025 | investing.com

Exicure announces issuance of new patent in Australia

March 15, 2025 | markets.businessinsider.com

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

March 13, 2025 | gurufocus.com

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm

January 27, 2025 | markets.businessinsider.com

Exicure announces purchase agreement with GPCR Therapeutics

January 24, 2025 | markets.businessinsider.com

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 23, 2025 | businesswire.com

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

When the Price of (XCUR) Talks, People Listen

January 21, 2025 | news.stocktradersdaily.com

When (XCUR) Moves Investors should Listen

January 11, 2025 | news.stocktradersdaily.com

(XCUR) Technical Pivots with Risk Controls

January 1, 2025 | news.stocktradersdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, INZY, GLUE, and TERN Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$4.89 -0.16 (-3.17%)

As of 11:40 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$3.98 +0.01 (+0.25%)

As of 11:40 AM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$3.98 -0.12 (-2.93%)

As of 11:44 AM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Exicure NASDAQ:XCUR

$8.96 -0.38 (-4.07%)

As of 11:38 AM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time